|
Re: NYAS Symposium on Apr 28
|
4
|
Resverlogix Corp.
|
Apr 21, 2016 04:03PM
|
|
Re: NYAS Symposium on Apr 28
|
4
|
Resverlogix Corp.
|
Apr 21, 2016 10:17PM
|
|
Re: NYAS Symposium on Apr 28
|
3
|
Resverlogix Corp.
|
Apr 27, 2016 03:01PM
|
|
Re: NYAS Symposium on Apr 28
|
3
|
Resverlogix Corp.
|
Apr 19, 2016 01:11PM
|
|
Re: NYAS Symposium on Apr 28
|
5
|
Resverlogix Corp.
|
Apr 22, 2016 11:12AM
|
|
Re: NYAS Symposium ...
|
4
|
Resverlogix Corp.
|
Apr 29, 2016 01:48PM
|
|
Re: NYAS Epigenetics: Cancer and Beyond Symposium eBriefing
|
4
|
Resverlogix Corp.
|
Jul 07, 2016 08:34PM
|
|
Re: NYAS Epigenetics: Cancer and Beyond Symposium eBriefing
|
4
|
Zenith Epigenetics
|
Jul 07, 2016 08:37PM
|
|
Re: NR: Resverlogix Highlights Key Accomplishments and 2018 Targets...
|
6
|
Resverlogix Corp.
|
Feb 08, 2018 08:54AM
|
|
Re: NR on phase 1 Kidney Trial
|
2
|
Resverlogix Corp.
|
Jan 23, 2017 11:45AM
|
|
Re: NR on phase 1 Kidney Trial
|
|
Resverlogix Corp.
|
Jan 23, 2017 12:08PM
|
|
Re: NR on Madrid conferece
|
1
|
Resverlogix Corp.
|
May 31, 2017 09:44AM
|
|
Re: NR
|
1
|
Resverlogix Corp.
|
Jan 23, 2017 11:19AM
|
|
Re: Now the webcast is up
|
2
|
Resverlogix Corp.
|
Mar 11, 2019 01:31PM
|
|
Re: Now the webcast is up
|
4
|
Resverlogix Corp.
|
Mar 11, 2019 01:52PM
|
|
Re: Now that we're a small cap stock....
|
5
|
Resverlogix Corp.
|
Jul 12, 2018 09:41AM
|
|
Re: Now that we're a small cap stock....
|
8
|
Resverlogix Corp.
|
Jul 12, 2018 12:10PM
|
|
Re: Now published: Rationale, design, and baseline characteristics of the BETonMACE trial
|
8
|
Resverlogix Corp.
|
Sep 16, 2019 02:21PM
|
|
Re: Now published: Rationale, design, and baseline characteristics of the BETonMACE trial
|
2
|
Resverlogix Corp.
|
Sep 16, 2019 03:05PM
|
|
Re: Now published: Rationale, design, and baseline characteristics of the BETonMACE trial
|
3
|
Resverlogix Corp.
|
Sep 16, 2019 04:22PM
|
